CureVac N.V.
General ticker "CVAC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $976.2M (TTM average)
CureVac N.V. follows the US Stock Market performance with the rate: 51.8%.
Estimated limits based on current volatility of 0.7%: low 4.62$, high 4.70$
Factors to consider:
- Total employees count: 554 as of 2020
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.97$, 5.17$]
- 2025-12-31 to 2026-12-31 estimated range: [2.09$, 5.34$]
Financial Metrics affecting the CVAC estimates:
- Positive: with PPE of 3.7 at the end of fiscal year the price was very low
- Positive: Operating profit margin, % of 33.20 > 18.31
- Positive: Operating cash flow per share per price, % of 15.58 > 12.91
- Negative: negative Industry operating cash flow (median)
- Negative: Inventory ratio change, % of 27.00 > 0.82
- Negative: negative Industry operating income (median)
Short-term CVAC quotes
Long-term CVAC plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €67.42MM | €53.76MM | €535.18MM |
| Operating Expenses | €316.88MM | €327.96MM | €357.50MM |
| Operating Income | €-249.46MM | €-274.21MM | €177.68MM |
| Non-Operating Income | €0.30MM | €14.24MM | €13.20MM |
| Interest Expense | €3.71MM | €2.49MM | €0.00MM |
| R&D Expense | €62.55MM | €115.72MM | €153.03MM |
| Income(Loss) | €-249.16MM | €-259.97MM | €190.88MM |
| Taxes | €0.00MM | €0.20MM | €0.00MM |
| Profit(Loss)* | €-249.03MM | €-260.17MM | €162.19MM |
| Stockholders Equity | €533.25MM | €516.94MM | €696.61MM |
| Inventory | €23.99MM | €24.80MM | €0.54MM |
| Assets | €860.47MM | €788.25MM | €802.83MM |
| Operating Cash Flow | €-286.18MM | €-267.89MM | €101.85MM |
| Capital expenditure | €93.22MM | €55.20MM | €18.44MM |
| Investing Cash Flow | €-93.50MM | €-55.20MM | €-18.44MM |
| Financing Cash Flow | €63.17MM | €230.89MM | €-5.11MM |
| Earnings Per Share** | €-1.32 | €-1.18 | €0.72 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.